275 related articles for article (PubMed ID: 27088457)
81. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Vangara KK; Liu JL; Palakurthi S
Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
[TBL] [Abstract][Full Text] [Related]
82. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro.
Keijzer C; Spiering R; Silva AL; van Eden W; Jiskoot W; Vervelde L; Broere F
J Control Release; 2013 May; 168(1):35-40. PubMed ID: 23500056
[TBL] [Abstract][Full Text] [Related]
83. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.
Saini V; Jain V; Sudheesh MS; Jaganathan KS; Murthy PK; Kohli DV
Int J Pharm; 2011 Apr; 408(1-2):50-7. PubMed ID: 21291968
[TBL] [Abstract][Full Text] [Related]
84. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
85. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles.
Stano A; Scott EA; Dane KY; Swartz MA; Hubbell JA
Biomaterials; 2013 Jun; 34(17):4339-46. PubMed ID: 23478034
[TBL] [Abstract][Full Text] [Related]
86. Preparation of Modified Konjac Glucomannan Nanoparticles and their Application as Vaccine Adjuvants to Promote Ovalbumin-Induced Immune Response in Mice.
Chen N; Zhu P; Du T; Han K; Wang D; Ye J; Xiao S; Ye X; Wang Y
Pharm Res; 2018 Mar; 35(5):105. PubMed ID: 29560565
[TBL] [Abstract][Full Text] [Related]
87. DEC-205 receptor targeted poly(lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease vaccine in mice.
Feng Y; Fan J; Wu D; Liu Q; Li H; Zhang X; Li S; Tang F; Liu Z; Zhang L; Feng H
Int J Biol Macromol; 2023 Feb; 227():576-589. PubMed ID: 36549613
[TBL] [Abstract][Full Text] [Related]
88. Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.
Li B; Siuta M; Bright V; Koktysh D; Matlock BK; Dumas ME; Zhu M; Holt A; Stec D; Deng S; Savage PB; Joyce S; Pham W
Int J Nanomedicine; 2016; 11():6103-6121. PubMed ID: 27895483
[TBL] [Abstract][Full Text] [Related]
89. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
90. Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors.
Liu C; Chu X; Yan M; Qi J; Liu H; Gao F; Gao R; Ma G; Ma Y
Int J Pharm; 2018 Dec; 553(1-2):327-337. PubMed ID: 30393151
[TBL] [Abstract][Full Text] [Related]
91. Nanotechnology-Based Cancer Vaccine.
Alshamsan A
Methods Mol Biol; 2017; 1530():257-270. PubMed ID: 28150207
[TBL] [Abstract][Full Text] [Related]
92. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
Rizwan SB; McBurney WT; Young K; Hanley T; Boyd BJ; Rades T; Hook S
J Control Release; 2013 Jan; 165(1):16-21. PubMed ID: 23142776
[TBL] [Abstract][Full Text] [Related]
93. In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4
Tang XD; Lü KL; Yu J; Du HJ; Fan CQ; Chen L
Cancer Immunol Immunother; 2022 Dec; 71(12):2969-2983. PubMed ID: 35546204
[TBL] [Abstract][Full Text] [Related]
94. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
95. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
96. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens.
Yang YW; Hsu PY
Biomaterials; 2008 Jun; 29(16):2516-26. PubMed ID: 18329708
[TBL] [Abstract][Full Text] [Related]
97. Nanomaterial-dependent immunoregulation of dendritic cells and its effects on biological activities of contraceptive nanovaccines.
Xu P; Tang S; Jiang L; Yang L; Zhang D; Feng S; Zhao T; Dong Y; He W; Wang R; Zhang J; Liang Z
J Control Release; 2016 Mar; 225():252-68. PubMed ID: 26826303
[TBL] [Abstract][Full Text] [Related]
98. Dendritic Cell-Targeted Nanovaccine Delivery System Prepared with an Immune-Active Polymer.
Rajput MKS; Kesharwani SS; Kumar S; Muley P; Narisetty S; Tummala H
ACS Appl Mater Interfaces; 2018 Aug; 10(33):27589-27602. PubMed ID: 30048112
[TBL] [Abstract][Full Text] [Related]
99. Cationic polymer-modified Alhagi honey polysaccharide PLGA nanoparticles as an adjuvant to induce strong and long-lasting immune responses.
Wusiman A; Jiang W; Yu L; Zhu T; He J; Liu Z; Bo R; Liu J; Wang D
Int J Biol Macromol; 2021 Apr; 177():370-382. PubMed ID: 33621572
[TBL] [Abstract][Full Text] [Related]
100. PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.
Dölen Y; Gileadi U; Chen JL; Valente M; Creemers JHA; Van Dinther EAW; van Riessen NK; Jäger E; Hruby M; Cerundolo V; Diken M; Figdor CG; de Vries IJM
Front Immunol; 2021; 12():641703. PubMed ID: 33717196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
